Atara Biotherapeutics, Inc.

Stage 2 · Advancing · week 2

As of Oct 22, 2026, Atara Biotherapeutics is in Stage 2, the uptrend phase, now in week 2 (since Oct 9, 2026). It closed at $9.43, 47.9% below its 52-week high and above its 200-day average, which is falling.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. More about the company

$9.43

+0.86% today

$94.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ATRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 23w

S4 28w

S2 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 23w → S1 10w → S4 28w → S1 9w → S2 4w → S3 3w → S4 12w → S1 9w → S2 24w → S3 4w → S4 11w → S1 11w → S2 3w → S3 9w → S2 2w current

Total tracked: 165 weeks across 16 stage runs.

ATRA among Biotechnology318th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…318	ATRAAtara Biotherapeutics, Inc.	Stage 2 · wk 2	28	+10.2%

vs 52W High

-47.9%

$4.18 lo$18.09 hi

47.9% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 2

1w13w26w

Week 2, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

22.0%

200 DMA: $7.73 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.51x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

→

Short-term trend flat

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+10.2%

+19.4%

+92.4%

YTD

-46.9%

-40.3%

Scan Membership

Breakout Watch

Latest: 2025-01-06

5 appearances in last 60 days. First seen: 2019-04-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 2 · Vol 0.51x

2026-10-21S2

Wk 2 · Vol 0.57x

2026-10-20S2

Wk 2 · Vol 0.33x

2026-10-19S2

Wk 2 · Vol 0.27x

2026-10-16S2

Wk 2 · Vol 0.43x

2026-10-15S2

Wk 1 · Vol 0.53x

2026-10-14S2

Wk 1 · Vol 0.86x

2026-10-13S2

Wk 1 · Vol 0.70x

2026-10-12S2

Wk 1 · Vol 0.58x

2026-10-09S23→2

Wk 1 · Vol 0.46x

2026-10-08S3

Wk 9 · Vol 0.60x

2026-10-07S3

Wk 9 · Vol 0.23x

Moving averages & range

50 DMA

$9.24

200 DMA

$7.73

52W High

$18.09

52W Low

$4.18

5D Low

$8.96

Resistance levels (recent highs)

20d High

$9.75

60d High

$10.23

120d High

$11.65

250d High

$18.09

Next resistance

+3.4%

to 20d High

Dividend Yield

0.00%

P/B -2.4

Atara Biotherapeutics: quick answers

What stage is Atara Biotherapeutics in?

As of Oct 22, 2026, Atara Biotherapeutics (ATRA) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 9, 2026 and is in week 2. What the four stages mean

Is Atara Biotherapeutics in an uptrend?

Yes. Atara Biotherapeutics is in a Stage 2 uptrend. It trades 22.0% above its 200-day average, which is falling.

How far is Atara Biotherapeutics from its 52-week high?

Atara Biotherapeutics closed at $9.43 on Oct 22, 2026, 47.9% below its 52-week high of $18.09. Its 52-week low is $4.18.

How has Atara Biotherapeutics performed over the past year?

As of Oct 22, 2026, Atara Biotherapeutics is down 40.3% over the past year and down 46.9% so far in 2026.

Which sector and industry is Atara Biotherapeutics in?

Atara Biotherapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.